title: Prolonged remission maintenance in acute myeloid leukaemia.
abstract: Twenty-five patients with acute myeloid leukaemia were treated with three quadruple drug combinations in predetermined rotation: TRAP (thioguanine, daunorubicin, cytarabine, prednisolone); COAP (cyclophosphamide, vincristine, cytarabine, prednisolone); and POMP (prednisolone, vincristine, methotrexate, mercaptopurine). Fifteen patients (60%) achieved complete remission and five (20%) partial remission. For maintenance, five-day courses of drugs were administered every 14 to 21 days and doses were increased to tolerance. The median length of complete remission was 66 weeks. In eight patients remission maintenance treatment was discontinued and some remained in complete remission for over two years. In this series the remission induction rate was comparable with that reported for other regimens and complete remission lasted longer with this intensive maintenance regimen than with others. Nevertheless, the TRAP programme must still be regarded as only palliative treatment for acute myeloid leukaemia.
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D003520:Cyclophosphamide / Q000627:therapeutic use; D003561:Cytarabine / Q000627:therapeutic use; D003630:Daunorubicin / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy*; D008297:Male; D015122:Mercaptopurine / Q000627:therapeutic use; D008727:Methotrexate / Q000627:therapeutic use; D008875:Middle Aged; D011239:Prednisolone / Q000627:therapeutic use; D012075:Remission, Spontaneous; D013866:Thioguanine / Q000627:therapeutic use; D014750:Vincristine / Q000627:therapeutic use
chemical_list: D000970:Antineoplastic Agents; D003561:Cytarabine; D014750:Vincristine; D003520:Cyclophosphamide; D011239:Prednisolone; D015122:Mercaptopurine; D013866:Thioguanine; D008727:Methotrexate; D003630:Daunorubicin
references.citation: Br J Cancer. 1977 Mar;35(3):265-72
references.pmid: 322689
references.citation: Cancer. 1971 Feb;27(2):247-56
references.pmid: 5100389
references.citation: Arch Intern Med. 1976 Nov;136(11):1256-61
references.pmid: 984987
references.citation: Lancet. 1974 Dec 14;2(7894):1405-9
references.pmid: 4140327
references.citation: Lancet. 1969 Feb 15;1(7590):330-3
references.pmid: 4179349
references.citation: Lancet. 1975 Oct 4;2(7936):621-4
references.pmid: 52000
references.citation: Semin Hematol. 1972 Apr;9(2):181-91
references.pmid: 4553226
references.citation: Cancer. 1972 Dec;30(6):1572-82
references.pmid: 4509106
references.citation: Br Med J. 1973 Jan 20;1(5846):131-7
references.pmid: 4513355
references.citation: Br Med J. 1970 Nov 28;4(5734):513-7
references.pmid: 4921703
references.citation: JAMA. 1971 Apr 26;216(4):648-52
references.pmid: 5279904
references.citation: Medicine (Baltimore). 1970 Nov;49(6):505-13
references.pmid: 5286084
references.citation: Clin Pharmacol Ther. 1971 Jul-Aug;12(4):599-606
references.pmid: 5284835
references.citation: Cancer. 1975 Aug;36(2):775-95
references.pmid: 1057450
references.citation: Arch Intern Med. 1976 Dec;136(12):1417-21
references.pmid: 793554